An analysis of ranibizumab treatment and visual outcomes in real-world settings: the UNCOVER study

Eldem B., Lai T. Y. Y. , Ngah N. F. , Vote B., Yu H. G. , Fabre A., ...More

GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, vol.256, no.5, pp.963-973, 2018 (SCI-Expanded) identifier identifier identifier


To describe intravitreal ranibizumab treatment frequency, clinical monitoring, and visual outcomes (including mean central retinal thickness [CRT] and visual acuity [VA] changes from baseline) in neovascular age-related macular degeneration (nAMD) in real-world settings across three ranibizumab reimbursement scenarios in the Middle East, North Africa, and the Asia-Pacific region.